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Abstract
Background: Limited data exists on the prevalence of heart failure amongst minority groups in the UK. To document the
community prevalence and severity of left ventricular systolic dysfunction, heart failure, and atrial fibrillation, amongst the
South Asian and Black African -Caribbean groups in the UK.
Methods s and Results: We conducted a cross-sectional study recruiting from September 2006 to July 2009 from 20 primary
care centres in Birmingham, UK. 10,902 eligible subjects invited, 5,408 participated (49.6%) and 5,354 had complete data
(49.1%). Subjects had median age 58.2 years (interquartile range 51.0 to 70.0), and 2544 (47.5%) were male. Of these, 1933
(36.3%) had BMI.30 kg/m
2, 1,563 (29.2%) had diabetes, 2676 (50.0%) had hypertension, 307 (5.7%) had a history of
myocardial infarction, and 104 (1.9%) had history of arrhythmia. Overall, 59 (1.1%) had an Ejection Fraction,40%, and of
these 40 (0.75%) were NYHA class $2; 51 subjects (0.95%) had atrial fibrillation. Of the remaining 19 patients with an
EF,40%, only 4 patients were treated with furosemide. A further 54 subjects had heart failure with preserved ejection
fraction.
Conclusions: This is the largest study of the prevalence of left ventricular systolic dysfunction, heart failure and atrial
fibrillation in under-researched minority communities in the UK. The prevalence of heart failure in these minority
communities appears comparable to that of the general population but less than anticipated given the high rates of
cardiovascular disease in these groups. Heart failure continues to be a major cause of morbidity in all ethnic groups and
preventive strategies need to be identified and implemented.
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Introduction
Heart failure (HF) is a major public health problem with global
implications. The epidemiology of heart failure has been well
characterised in the USA [1,2,3,4] and Europe [5,6] predom-
inantly amongst the white population. Surveys in the United
Kingdom (UK) and elsewhere report that 1–2% of the general
population and 10–20% of the very elderly have HF [7,8,9].
However, limited data on ethnicity and heart failure are available
outside North America and mainly amongst Black Americans.
[10] Such information would inform healthcare provision as well
as clinical management strategies, given the increasing number of
ethnic minority groups in the UK. Further there is a need to
increase data from minority groups in order to reduce racial and
ethnic disparities in cardiovascular outcomes [11].
Heart failure directly accounts for 1.9% of total National Health
Service (NHS) spending in the UK, with 69% of this being on
hospitalisations, and indirectly (via long-term nursing care costs and
secondary admissions) for a further equivalent of 2.0% of NHS
expenditure [12]. Whilst there are well-established drug treatments
for heart failure [1,13], ethnic groups may respond differently to
these therapies. [14,15,16] Further a large primary care based study
in the UK, the Echocardiographic Heart of England Screening
(ECHOES) study, reported that the prevalence of symptomatic left
ventricular systolic dysfunction (LVSD) in a predominantly White
population aged 45 and older was 0.96% [7].
There were 4.6 million people (7.9%) from the Black and
minority ethnic groups in the 2001 UK Census, and the Black
African-Caribbean, Indian, Pakistani and Bangladeshi groups
comprised 2%, 1.8%, 1.3%, 0.5% respectively [17]. Importantly,
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amongst these ethnic groups than the White population. [17,18]
The prevalence of HF amongst these UK minority ethnic groups is
currently not known as these groups have been underrepresented
in previous studies [10].
The objective of the Ethnic-Echocardiographic Heart of Eng-
land Screening study (E-ECHOES) was to establish the commu-
nity prevalence and severity of LVSD and HF amongst the South
Asian (SA) and Black African-Caribbean (AC) ethnic groups in the
UK. Further objectives were to assess the prevalence of atrial
fibrillation, and the differences, if any, in heart failure risk factors
between SA and AC ethnic populations.
Methods
Ethics Statement
This study complies with the Declaration of Helsinki and the
Walsall Local Research Ethics Committee reviewed and approved
the protocol (05/Q2708/45). Verbal and written consent was
obtained from all participants.
Study population. The design and protocol of the E-
ECHOES study has previously been published [19]. In brief,
this was a cross-sectional population survey of a sample of SA (i.e.
those originating from India, Pakistan or Bangladesh) and AC (i.e.
those originating from the Caribbean and sub-Saharan Africa)
residents of Birmingham aged 45 years and over. The majority of
the SA and AC groups in the UK reside in metropolitan areas
particularly inner cities such as Birmingham [17].
Recruitment was undertaken from September 2006 to August
2009 from 20 primary care centres. This entailed a two-staged
process with an initial sample of primary care centres known to
have high proportion of these minority ethnic patients and then a
sample using the practice age-sex register. As ethnic group col-
lection is not routinely collected in primary care, we used multiple
methods to identify the subjects. Potential SAs were identified
using the Nam Pechan software based upon subject name and
visual inspection by PSG [20]; and for AC subjects practice staff
were consulted (see Figure 1). The general practitioner then
reviewed the lists to ensure that only SA and AC subjects were
included and excluded any whom they considered it inappropriate
to approach; for example, due to terminal illness or dementia.
Potential subjects were mailed an invitation letter, a reminder
and telephoned up to 3 times inviting them to participate in the
study. All potentially eligible subjects were asked their ethnic
group before booking an appointment.
Measurements. To maximise recruitment, we invited all
eligible subjects to attend for an assessment at their local primary
Figure 1. Flow of participants through study.
doi:10.1371/journal.pone.0026710.g001
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comprehensive questionnaire, full physical examination, ECG and
echocardiogram. Interpreters were used as required. Self-reported
diagnoses were confirmed with practice medical notes.
A resting 12 lead ECG was recorded and reported by the cli-
nical research team, and a random sample was reported indepen-
dently by 3 consultant cardiologists (RD, MD, GL). Echocardi-
ography was performed within the general practice surgeries using
a portable VIVID i machine (GE Healthcare, Chalfont St Giles,
UK), Chamber dimensions were obtained from the parasternal
windows, and the presence and degree of left ventricular hyper-
trophy noted. Left ventricular function was measured objectively
using an area-length method from the apical four-chamber view.
In cases where an objective measurement of left ventricular ejec-
tion fraction (LVEF) was not possible, a qualitative assessment was
made, that is, definite impairment (LVEF,40%), borderline (40–
50%) and preserved (.50%), consistent with the investigators’
normal clinical practice (RD, MD, GYHL). Valve disease was
assessed semi-quantitatively and recorded, along with any other
abnormalities. Parameters of diastolic function (mitral valve E:A
ratio; E wave deceleration time; and isovolumic relaxation time,
and Pulsed Wave Tissue Doppler studies of movement of the
mitral valve annulus, with derivation of the E:e prime ratio) were
also measured. Heart Failure, both systolic and with preserved
ejection fraction (HFPEF), was defined using explicit criteria [13].
Quality control measures
The research team were given training at the start of the project
on administering the questionnaire; performing physical exami-
nation, followed by an ECG and echocardiogram. The team
followed written protocols that included a number of quality
control checks, including re-reporting by senior cardiologists (RD,
MD) of all abnormal echocardiograms and a sample of those
reported by the research fellow as normal. Both RD and MD
undertook quality assurance in the ECHOES study [7].
Sample Size and statistical analysis
Full details of the sample size and analysis plan have previously
been provided in the E-ECHOES protocol paper [19]. Briefly, we
aimed to recruit 3000 SA and 2000 AC patients. The precision of
estimation of prevalence is dependent upon the number of subjects
and the prevalence rate. The principal aims of this study were to
estimate the prevalence of LVSD and heart failure, and atrial
fibrillation, in the SA and AC populations.
Descriptive analyses were performed on all study variables, de-
scribing rates as percentages, and continuous variables as medians
and lower and upper quartiles. Prevalence estimates are described
with 95% confidence intervals. For the comparisons of heart fai-
lure rates by survey, a test for interaction was used and confidence
intervals presented [21]. Descriptive data were compared to those
from the ECHOES study where LVSD was assessed amongst a
predominantly White population [7]. Due to the small number of
cases, age-sex adjustment was not conducted.
Results
Subjects
Of 13,097 subjects screened , 10,902 were eligible and invited
and 420 (3.2%) did not meet the study inclusion criteria. 6,506
(59.7% of those eligible and invited had an appointment booked of
which5,408 (49.6%) completing the screening process and 5,354
(%) having complete LVEF data (Figure 2).
Table 1 shows that for AC group, non-responders were likely to
be younger males from less deprived areas in contrast SA non-
responders who were likely to be males from deprived areas. The
conclusions are the same for those subjects potentially eligible (Table
S1) for this study (i.e. those unable to participate due to being
abroad; change of practice or ill health/disability).
Of those with complete LVEF data, 3442 (64.28%) were SA and
1912 (37.71%) were AC subjects. Subject demographics are
summarised in Table 2. The median age of participants was 58.2
years (IQR, interquartile range: 51.0 to 70.0) of which 2810 (52.5%)
were female. The average deprivation index was 58.2 for the whole
cohort, with SA being lower (56.8) and AC being higher (64.0). The
proportion of patients with hypertension or diabetes was relatively
high in both groups (hypertension: 45.6% of SA and 57.9% of AC;
diabetes 30.8% and 26.3%, respectively). Table S2 shows clinical
characteristics of all subjects by ethnic group and ejection fraction.
Prevalence of Left-Ventricular Systolic Dysfunction and
Symptomatic Heart Failure. In the whole cohort, 59 subjects
(1.1%; 95% CI 0.84 to 1.42%) had an LVEF,40% (Table 3). Of
these 40 had symptoms of dyspnoea with NYHA$2. Of the
remaining 19 patients with an LVEFEF,40% four patients were
treated with furosemide, so presumably had had previous symp-
toms of heart failure.
In SA, 42 subjects (1.22%; 95% CI 0.88 to 1.65%) had an
LVEF,40%, with mean age of 67.0 years(SD 9.9) of which 29
(69.05%) were male. In AC, 17 (0.89%; 95% CI 0.52 to 1.42%)
had an LVEF,40% with a mean age of 72.4 years (SD 11.0), of
which 15 (88.24%) were males. The prevalence of LVSD in the
SA population is not statistically different from the prevalence
observed in the AC population.
Table 4 shows that symptomatic heart failure occurred in 26
subjects with no underlying valve disease or atrial fibrillation.
Of the 40 patients with an LVEF,40% and NYHA$22 5
(62.5%) were prescribed an ACE inhibitor and 18 (45%) were
prescribed a beta-blocker. Of the 19 patients with an LVEF,40%
but without symptoms four patients were treated with furosemide
(3 patients 40 mg daily; 1 patient 160 mg daily). Table 3 shows
that the prevalence of systolic heart failure is not statistically
different between the SA and AC groups.
Point prevalence of atrial fibrillation
Overall, 51 subjects (0.95%; 0.71 to 1.25%) had atrial fibrillation:
26 (1.36%; 95% CI 0.89 to 1.99%) AC patients had evidence of
atrial fibrillation with a mean CHADS2 score of 2.3 (SD 1.0whilst
25 (0.73%; 95% CI 0.47 to 1.07%) SA patients had evidence of
atrial fibrillation with a mean CHADS2 score of 2.5 (SD 1.4) .
Left ventricular systolic dysfunction in high risk popula-
tions and a prior diagnosis of heart failure. Overall, 75
subjects (1.40%) reported a medical history of heart failure. Of the
59 patients identified with a LVEF,40%, 23 (39.0%) had a prior
diagnosis of heart failure. A further 52 patients reported heart
failure of which 13 patients had an EF of 40 to 50% and the
remaining 39 patients had an LVEF.50%.
Heart failure with preserved ejection fraction (diastolic
heart failure). Table 4 shows causes of heart failure with 54
subjects (AC 16 ; SA 38) classified with definite heart failure with
preserved ejection fraction. The majority (37) had no underlying
valve disease or atrial fibrillation. All patients with definite heart
failure with preserved ejection fraction had NYHA$2.
Discussion
In this first large community based epidemiological study, we
have documented the prevalence of LVSD (SA: 1.22%; 95% CI
0.88 to 1.65%; AC: 0.89%; 95% CI 0.52 to 1.42%) and heart
failure (SA: 0.81%; 95% CI 0.54 to 1.17%; AC: 0.63%; 95% CI
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we report the first epidemiological data on the prevalence of atrial
fibrillation in these subjects (0.95%; 95% CI 0.71 to 1.25%).
The overall prevalence (0.75%) of HF was similar to that
documented in primary care for the general population in England
(0.7%) [22]. It was surprising to note that this was not higher given
that SAs living in the UK, have a 50% greater risk of dying pre-
maturely from coronary heart disease than the general population.
A reanalysis of the data from our own study of acute HF
admissions to a UK hospital [23] had suggested that the relative
risk of HF in those aged 60–79 years was 3.1 (95% CI 1.9–4.9) for
AC, and 5.2 (95% CI 3.7–7.4) for SA. The present community
study does not support this, with a lower prevalence of HF in both
ethnic groups. The lower rates of LVSD and HF in our cohort
could conceivably reflect higher rates of myocardial infarction
fatality though recent observational studies suggest otherwise
[24,25]. Of note, the misdiagnosis of HF is a possibility, given the
high number of patients with normal ejection fraction that had
diagnosis of heart failure, but levels are broadly consistent with
those seen in the predominantly white community study [7]. As
the latter study was undertaken more than 10 years ago (between
1995–1999), there needs to be caution in comparing these data.
Another plausible explanation is the reduction of cardiovascular
risk factors during the past decade that has prevented the
occurrence of HF amongst these groups [26]. Further, nearly
two-third of the subjects were taking drugs such as diuretics and
ACE inhibitors and prescription items for ACE inhibitors and
AIIRAs have been increasing that may potentially have alleviated
progression to heart failure [27,28].
We found that the mean age of HF amongst SA and AC groups
is similar to that amongst the White population [7]. In contrast,
African Americans have been reported to have a higher
Figure 2. Study profile.
doi:10.1371/journal.pone.0026710.g002
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age [4]. The aetiology of HF is not known amongst the latter
group and is unlikely to be due to coronary artery disease as in our
study sample [29]. However, there is a higher prevalence of
hypertension amongst the AC communities, which is a major
cause of HFPEF or so-called ‘diastolic dysfunction’ [1]. This
suggests that the HF epidemiology of US African Americans and
UK AC populations may be different [30]. We also report for the
first time prevalence estimates of HFPEF amongst these minority
ethnic communities as assessed by robust Doppler criteria and
observed that HFPEF appears higher amongst SA than the AC
groups. Most management strategies have focussed on heart
failure with LVSD and management of HFPEF remains elusive
[1,30].
The prevalence of hypertension and diabetes in participants
with LVSD appears higher in these 2 minority ethic groups than in
the White population (prevalence hypertension SA 78.6%; AC
76.5%; White British 39%; prevalence diabetes SA 40.5%; AC
58.8%; White 15%) [7]. The myocardial ischaemia rate, however,
is comparable amongst the SA (54.8%) and White (53%) groups
[7] and much lower amongst the AC group (41.2%). The latter is
in line with data from the US where HF in Black Americans is less
likely to be due to coronary heart disease than that in whites [1].
Galasko et al [31] showed that in a community sample that there
was no difference in prevalence of LVSD between the white and
non-white ethnic groups. However only 188 SA subjects were
included with a higher cut-off LVEF,45%. It was also surprising
to note the low numbers of HF associated with valve disease in our
cohort given the burden of rheumatic heart disease in India [32]
and our subjects migrating to the UK as young adults (median age
22 years for SA [IQR 17–30] and AC [IQR 16–28]).
Some data on HF in hospitalized ethnic groups are available
from the UK. In a study conducted in Leicestershire involving
5789 consecutive patients [33], admission rates for HF were higher
among SA patients than white patients. In this cohort, SA patients
were younger and had more diabetes than white patients. In our
analysis of acute admissions with HF to a district general hospital
serving a multiracial population, we observed a higher short term
(in-patient) mortality amongst the white European patients – with
the mortality being 20.7% amongst Europeans, compared to 8.7%
amongst AC, and 13.2% amongst SA – but the differences did not
reach statistical significance [34]. At 8 years’ follow-up, the total
mortality was 90.5% amongst whites and 87.0% amongst non-
whites (Log Rank test, p=0.07) where the non-white patients had
significantly better survival at all time points until 6 years, after
which the survival curves started to converge [34]. In a matched
historical cohort study of patients hospitalized for HF from
Leicestershire [35], SA patients had similar rates of prior coronary
artery disease but more often had hypertension and diabetes. As
well as methodological issues these studies were conducted in
secondary care, and have focused on particular ethnic groups by
aggregating the groups, thus masking the differences that exist
between minority ethnic groups, particularly the SA category [36].
Further community-based studies documenting the incidence of
heart failure are needed.
Atrial Fibrillation
The prevalence of AF was low in both ethnic groups, consistent
with published small scale data. In the UK, one case-note review
of known AF cases in 6 general practices, reported an AF
prevalence of 0.6% [37], a figure consistent with our present
observations from a large community screening study. Note that
this does not include individuals with paroxysmal AF in sinus
rhythm at the time of the investigation so may underestimate the
true prevalence figure.
Strengths and Limitations of the study. Our study has
several strengths: first it has a large sample of under-represented
hard to reach groups [16] drawn from 20 centres increasing
generalisability to these minority ethnic groups. Secondly, we used
current guidelines on diagnosis of HF [13]. Thirdly, we used
standard methods across both groups as in the previous study
amongst the White population [7]. Fourthly, missing EF data was
less than 1% in those having an echocardiogram.
There are potential limitations of our study. The response rate
was low (49.6%), an increasingly common problem in epidemi-
ological research, particularly amongst ethnic minority groups
[38,39,40]. However this was comparable to similar heart failure
community studies amongst minority [31] and white groups
[7,8,41]. Indeed 6,506 (59.6%) make an appointment; 1,098
(16.9%) did not attend. (Fig. 2), 1,493 (26.7%) were confirmed to
be no longer residing at the given address and the rest were not
contactable despite the written and 3 telephone reminders. Further
Table 1. Characteristics of responders and non-responders.
Responders with
Ejection Fraction data Non responders Difference in Means (95% CI) P Value
South Asians (n,%) 3442(53.4) 3007(46.6)
Age at initial contact (mean [SD], years) 59.4 (10.4) 59.5 (11.2) 20.0009 (20.0054 to 0.0037) 0.71
Index of Multiple Deprivation 2007 (mean [SD]) 49.4 (15.8) 52.6 (13.9) 20.017 (20.020 to 20.0129) ,.0001
Odds Ratio (95% CI)
Male (n, %) 1690 (49.1%) 1566 (52.1%) 1.12 (1.02 to 1.24) 0.02
African Caribbean (n,%) 1912(42.9) 2541(57.1)
Age at initial contact (mean [SD], years) 62.5 (12.0) 59.7 (12.2) 0.0158 (0.0106 to 0.021) ,.0001
Index of Multiple Deprivation 2007 (mean [SD]) 53.4 (12.6) 52.7 (14.1) 0.0076 (0.0026 to 0.0126) 0.0029
Odds Ratio (95% CI)*
Male (n, %) 854 (44.7%) 1302 (51.2%) 1.34 (1.18 to 1.52) ,.0001
Univariate analyses with practice as random effects;
*Odds ratio for response: female compared to male.
Index of Multiple Deprivation 2007 Score: higher scores indicate increased deprivation. [http://www.communities.gov.uk/communities/research/indicesdeprivation/].
doi:10.1371/journal.pone.0026710.t001
Heart Failure Amongst Minority Ethnic Groups
PLoS ONE | www.plosone.org 5 November 2011 | Volume 6 | Issue 11 | e26710Table 2. Clinical characteristics of all subjects by ethnic group.
* SA Total (n=3442) AC Total (n=1912) p value
Age (mean [SD], years) 59.7 (10.4) 62.7 (12.0) ,0.0001
Male 1690 (49.10%) 854 (44.67%) 0.0019
Systolic blood pressure
(Mean, SD, mm Hg)
139.51 (19.85) 144.32 (19.88) ,0.0001
Diastolic blood pressure
(Mean, SD, mm Hg)
80.87 (10.91) 81.99 (10.79) 0.0003
Ever smoked 801 (23.27%) 826 (43.20%) ,0.0001
Consumes alcohol
(occasionallyor regularly)
552 (16.04%) 1306 (68.31%) ,0.0001
BMI Median (IQR) 27.56 (24.89
to 31.13)
28.99(25.89
to 33.05)
Index of Multiple Deprivation
2007 Median, IQR
54.74(39.02
to 61.39)
57.93 (46.25
to 61.34)
,0.0001
New York Heart
Association Class
,0.0001
I 154 (4.47%){ 82 (4.29%){ 0.7515
II 81 (2.35%) 42 (2.20%) 0.714
III 16 (0.46%) 8 (0.42%) 0.8075
IV 0 (0%) 0 (0%) -
EQ-5D Median (IQR) 1 (0.848 to 1) 1 (1 to 1) ,0.0001
Hypertension 1570 (45.61%) 1106 (57.85%) ,0.0001
Angina 328 (9.53%) 87 (4.55%) ,0.0001
Myocardial infarction/ACS/Revascularisation(PCI/CABG)* 299 (8.69%) 64 (3.35%) ,0.0001
Heart Failure 46 (1.34%) 29 (1.52%) 0.5474
Diabetes 1060 (30.80%) 503 (26.31%) 0.0005
Peripheral artery disease 18 (0.52%) 26 (1.36%) 0.0015
Stroke/TIA 157 (4.56%) 67 (3.50%) 0.0554
ACE Inhibitors 818 (23.77%) 465(24.32%) 0.6486
Diuretics 639 (18.56%) 616 (32.22%) ,0.0001
Beta-blockers 470 (13.65%) 236 (12.4%) 0.1741
Calcium Antagonists 613 (17.81%) 716 (37.45%) ,0.0001
Aspirin 1054 (30.62%) 563 (29.45%) 0.3691
Warfarin 35 (1.02%) 34 (1.78%) 0.0239
Digoxin 13 (0.38%) 13 (0.68%) 0.1077
Lipid regulating drugs 1483 (43.09%) 731 (38.23%) 0.0006
SA South Asian; AC African-Caribbean; BMI Body Mass Index, TIA Transient Ischaemic Attack; EQ-5D EuroQol 5D instrument;
{New York Heart Association Class reported only in those with cardiac disease;
*includes 1 Singalese subject with no heart failure.
doi:10.1371/journal.pone.0026710.t002
Table 3. Prevalence of Left Ventricular Systolic Dysfunction and Heart Failure (%).
South Asian Black African-Caribbean All
3442 1912 5354
EF (%)
,40 42 (1.22%; 95% CI 0.88 to 1.65%) 17 (0.89%; 95% CI 0.52 to 1.42%) 59 (1.10%; 95% CI 0.84 to 1.42%)
40 to 50 41 (1.19%; 95% CI 0.86 to 1.61%) 16 (0.84%; 95% CI 0.48 to 1.36%) 57 (1.06%;95% CI 0.81 to 1.38%)
.50 3359 (97.59%; 95% CI 97.02 to 98.07%) 1879 (98.27%; 95% CI 97.58 to 98.81%) 5238 (97.83%; 95% CI 97.41 to 98.21%)
LV Systolic Heart Failure
EF,40 and NYHA$2 28 (0.81%; 95% CI 0.54 to 1.17%) 12 (0.63%; 95% CI 0.32 to 1.09%) 40 (0.75%; 95% CI 0.53 to 1.02%)
EF Ejection Fraction.
NYHA New York Heart Association.
doi:10.1371/journal.pone.0026710.t003
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the population it is difficult for primary care to maintain accurate
registers [42].
Indeed these 2 minority ethnic groups are perceived to be reluc-
tant to engage in research [16,40], and we achieved the relatively
high response by employing a number of strategies such as using
multilingual research staff to telephone the subjects after the initial
postal invitation; increasing awareness of the study within the
community and engaging with practice staff. Further, comorbid-
ities such as diabetes and hypertension were in line to those expect-
ed amongst these minority ethnic communities with, for example,
diabetes being up to 5–6 times higher amongst SAs compared to
the White group [17].
Also some subjects may not have attended for screening due to
illness or disability and we have 102 subjects who stated this reason
for non-attendance though none had a history of HF documented
by the centre. We also minimised bias in analysis by ensuring data
verification and locking the database before analysis. However, 1
Singhalese subject was included in the analysis and did not affect
the main results (Table 2). iven the low prevalence of HF we were
unable to evaluate predictors of HF as originally planned.
Conclusion. We have shown that the prevalence of HF and
AF in the under-researched SA and AC minority communities in
the UK appears comparable to that of the general population. HF
and atrial fibrillation will continue to be a major cause of mor-
bidity in all ethnic groups due to ageing of the population; and
preventive strategies need to be identified and implemented.
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